Lewis rats were liver allograft donors and recipients, respectively, in four groups: (A) syngeneic control, (B) blank control, (C) rAAV-enhanced green fluorescent protein negative control, (D) rAAV-hCTLA4Ig. Gene transfers occurred 6 weeks before transplantation.
Induced Liver Allograft Immunological
Tolerance in Rats by Intramuscular Injection of Recombinant Adenoassociated Virus-Human Cytotoxic T-lymphocyte-associated Antigen-4 Immunoglobulin (rAAV-hCTLA4Ig)
Introduction
Liver transplantation has already become a normal and valid means of treating latestage liver disease; however, the immunological rejection reaction is still the main factor affecting the period of liver-graft survival. The engagement of both the T-cell receptor (in association with major histocompatibility complex molecules) and the co-stimulatory signal by CD28/B7 is required for the initiation of T-cell-mediated immune responses. The cytotoxic T-Induced liver allograft immunological tolerance lymphocyte-associated antigen-4 immunoglobulin G (CTLA4Ig) fusion protein is a proven immune-modulation molecule that can provide a negative signal to T-cell activation, through competitive binding to B7 molecules on antigen-presenting cells, and, therefore, reduce graft rejection. Several studies have been undertaken to address the mechanism of co-stimulatory blockade by CTLA4Ig such as T-cell anergy, suppression and deletion. 1 -3 A long time period and/or high-level expression of the healing genes are needed to induce allograft immunological tolerance by blocking the T-cell co-stimulus signals. 4 Adeno-associated virus (AAV) vectors have been widely used because they have advantages, such as low immunogenicity, ability to transduce both dividing and non-dividing cells and the potential to integrate, to achieve long-term gene expression even in vivo. 5 They are potent delivery vehicles for gene-transfer strategies that are directed at muscle and liver. The AAV-derived vectors have been successfully used for the long-term expression of therapeutic genes in animal models and patients. The present study used nonpathogenic and low-toxicity recombinant AAV (rAAV) vectors to deliver CTLA4Ig genes into recipients by intramuscular injection, in order to induce liver allograft immunological tolerance in rats.
Materials and methods

CONSTRUCTION OF RAAV
The rAAV pSNAV1 vector plasmid was constructed by replacing the viral replicable genes, rep and cap, with a human cytomegalovirus promoter and enhancer, a multiple-cloning site, a neomycin-resistant gene, a simian virus 40 promoter and a polyadenylation signal, retaining the two inverted terminal repeats intact. Enhanced green fluorescent protein (EGFP) or human CTLA4Ig (hCTLA4Ig) fusion protein genes were inserted into the site between SalII and BglII, in the multiple-cloning site. 5
ANIMALS AND EXPERIMENTAL GROUPS
Adult male Dark Agouti (DA, RT1a) and Lewis (LEW, RT1l) rats weighing 200 -300 g were purchased from the Experimental Animal Centre of the Second Affiliated Hospital of Harbin Medical University, Harbin, China, and from Beijing Vital River Ltd, Beijing, China, respectively. The DA rats were used as donors and the LEW rats as recipients for liver allografts. The recipients' weights were similar to those of the donors, and both were maintained under standard conditions and cared for according to international guidelines. 6 Transplants from LEW to LEW served as syngeneic controls. Animal survival was regarded as graft survival. The experimental groups were: syngeneic control (LEW to LEW), n = 7 (group A); blank control, n = 10 (no treatment; group B); rAAV-EGFP, n = 10 (negative control; group C); and rAAV-hCTLA4Ig, n = 10 (group D). All gene transfers were accomplished 6 weeks before transplantation by intramuscular injection to the right hind limb of recipients at a dosage of 1.0 × 10 12 vg/kg. The orthotopic liver transplantation model was performed according to the cuff technique described by Kamada and Calne. 7 
HISTOLOGICAL STUDIES
Grafts were harvested at post-operative weeks 1, 4 and 12 (three per group) and at the time when the recipients died. Half of the grafts were fixed in buffered 10% formalin solution and embedded in paraffin for histological examination after haematoxylin and eosin staining. The other half were snap-frozen in liquid nitrogen and stored at -80°C for immunohistochemical Induced liver allograft immunological tolerance study and intra-graft cytokine expression analysis. Frozen tissues were cut into 5 µm sections for studying the phenotypes of infiltrated lymphocytes by immunohistochemical staining with mouse anti-rat CD4, CD8 monoclonal antibodies (AbD Serotec, Oxford, UK). At the same time, the right lower limbs were harvested for detection of CTLA4Ig by immunohistochemical staining with mouse anti-human CTLA4 polyclonal antibody (BD PharMingen™, San Diego, CA, USA). The sections were incubated with primary antibody for 2 h at room temperature, followed by 1 h incubation with horseradish peroxidase-conjugated goat anti-mouse antibody (SP9000; Zhong Shan Golden Bridge Biotechnology, Beijing, China). Colour development was performed in substrate solution with diaminobenzidine for 5 min. The slides were then counterstained with haematoxylin and eosin. Five fields were randomly chosen on each section, and positive-stained cells were counted under ×400 magnification.
PLASMA HCTLA4 LEVELS
Plasma was collected at post-operative weeks 1, 2, 4, 6, 8, 10 and 12 for determining soluble hCTLA4 levels in plasma by sandwich enzyme-linked immunosorbent assay. Purified recombinant hCTLA4/Fc protein was used as a standard. Purified mouse anti-hCTLA4 polyclonal antibody was used as the first antibody (BD PharMingen™, San Diego, CA, USA).
INTRA-GRAFT MRNA EXPRESSION
Snap-frozen graft tissue was homogenized and mRNA was extracted for analysis of interleukin-2 (IL-2), interferon-γ (IFN-γ), granzyme B and lymphotoxin β expression by reverse transcriptase-polymerase chain reaction (RT-PCR). The RT-PCR reagents for mRNA extraction and first-strand synthesis were purchased from Promega Biosciences (San Luis Obispo, CA, USA. As a template for the first-strand DNA reaction, 5 µg mRNA was used. Primers specific for different cytokines were designed as described previously. 8, 9 The PCR reactions were performed through reverse transcriptase incubation at 94°C for 2 min and 40 cycles of 85°C for 1 min, 60°C for 1 min and 72°C for 1 min. Relative cytokine expression was evaluated from the optical density ratio between samples and β-actin.
STATISTICAL ANALYSIS
Graft survival was analysed by the log-rank test. Other analyses were performed by the Student's t-test. P-values < 0.05 were considered to be statistically significant.
Results
SURVIVAL TIME
Rats injected with rAAV-hCTLA4Ig (group D) had a significantly prolonged survival time following liver graft (> 100 days; P < 0.01), compared with the negative control (group C; 11.9 ± 1.3 days) and blank control (group B; 11.6 ± 1.1 days). There were no significant differences between groups A and D, and between groups B and C.
PLASMA LEVELS OF HCTLA4
Plasma levels of hCTLA4Ig gradually increased in group D, especially after transplantation, peaking at 2 weeks after transplantation, and levels remained above the baseline until the last measurement at 12 weeks post-operation ( Fig. 1 ).
EXPRESSION OF HCTLA4 IN MUSCLE
The immunohistochemical examination of muscle showed hCTLA4Ig expression at the injection point in group D at 1, 4 and 12 weeks post-operation (Fig. 2 ).
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INFILTRATION OF LYMPHOCYTES IN GRAFTS
Severe rejection responses and large amounts of CD4 + and CD8 + T-lymphocyte infiltration were observed in groups B and C, whereas histological examination revealed only mild responses and few T-cells in group D (Figs 3 and 4 ).
RT-PCR TESTS
There were no significant differences in IL-2 and IFN-γ levels in liver grafts between groups D and C, whereas there were significant decreases in granzyme B and lymphotoxin β levels in group D compared with group C (P < 0.05; Fig. 5 ).
Discussion
One approach for introducing CTLA4Ig to allografts is through viral vectors, however it usually takes 4 -8 weeks for the therapeutic gene product carried by AAV to reach its expression peak after gene transfer, 10 which limits its use to donor-organ pre-treatment. Intramuscular injection is easy to perform and has been proven to be a valid method to transfer therapeutic genes carried by AAV. 11 The present study showed detection of hCTLA4Ig expression not only at the injection point but also in the recipients' plasma, that lasted for a relatively long period and may induce allograft immunotolerance. No sideeffects of long-term hCTLA4Ig expression were observed in recipients, but more studies are needed to confirm this. It has been reported that DA-LEW is a rat liver transplant model with a high rejection rate, 12, 13 and a mean survival time (without drugs) of approximately 11 days has been reported. 14 The control results of the present study are in accordance with this. The hCTLA4Ig gene transfer group, however, had a significantly longer survival period, and only mild to moderate rejection reactions were observed in the allograft, which confirms that hCTLA4Ig gene transferred by intramuscular injection was valid for blocking the co-stimulatory signals of the immune response to allografts. The study of Newell et al. 15 showed that blocking the CD28/B7 co-stimulatory signal generally decreased the level of CD4 + cell infiltration and T-helper (Th)1 cytokine downregulation, and/or Th2 cytokine upregulation. However, levels of IL-2 and IFN-γ were not seen to be down-regulated in the present study, whereas levels of granzyme B and lymphotoxin β were significantly downregulated, as reported in some studies. 16, 17 This shows that hCTLA4Ig gene transfer can also inhibit CD8 + T-lymphocytes.
In conclusion, the intramuscular injection of rAAV-hCTLA4Ig appears to prolong allograft survival significantly and is a safe and effective method of gene transfer that is easily performed.
